400 related articles for article (PubMed ID: 34676662)
1. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Ori A; Fiocchi M; Zagni E
Dermatol Ther; 2022 Jan; 35(1):e15166. PubMed ID: 34676662
[TBL] [Abstract][Full Text] [Related]
2. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study.
Zagni E; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Zullo A; Fiocchi M; Colombo D
BMC Health Serv Res; 2021 Sep; 21(1):924. PubMed ID: 34488749
[TBL] [Abstract][Full Text] [Related]
3. The CANOVA Study Real-World Evidence of Biologic Treatments in Moderate-Severe Psoriasis in Italy: A Gender Perspective.
Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Zullo A; Ferri F; Fiocchi M; Zagni E
Womens Health Rep (New Rochelle); 2022; 3(1):450-457. PubMed ID: 35651996
[TBL] [Abstract][Full Text] [Related]
4. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
Pinter A; Puig L; Schäkel K; Reich A; Zaheri S; Costanzo A; Tsai TF; Smith SD; Lynde C; Brnabic A; Reed C; Hill J; Schuster C; Riedl E; Paul C
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2087-2100. PubMed ID: 35766124
[TBL] [Abstract][Full Text] [Related]
6. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
Ioannides D; Antonakopoulos N; Georgiou S; Chasapi V; Katsantonis I; Drosos A; Rigopoulos D; Antoniou C; Anastasiadis G; Bassukas I; Ioannidou D; Protopapa A; Neofotistou O; Krasagakis K; Aronis P; Papageorgiou M; Lazaridou E; Patsatsi A; Lefaki I; Roussaki-Schulze AV; Satra F; Anagnostopoulos Z; Papakonstantis M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1838-1848. PubMed ID: 34036627
[TBL] [Abstract][Full Text] [Related]
8. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
[TBL] [Abstract][Full Text] [Related]
9. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).
Foley P; Manuelpillai N; Dolianitis C; Cains GD; Mate E; Tronnberg R; Baker C
Australas J Dermatol; 2022 Aug; 63(3):303-311. PubMed ID: 35809080
[TBL] [Abstract][Full Text] [Related]
11. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
[TBL] [Abstract][Full Text] [Related]
12. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
Pinter A; Eyerich K; Costanzo A; Garrelts A; Schuster C; Mert C; Lampropoulou A; Fotiou K; Maul JT; Papp KA
J Dermatolog Treat; 2024 Dec; 35(1):2350227. PubMed ID: 38797734
[TBL] [Abstract][Full Text] [Related]
13. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study.
Ying L; Suyun J; Yanhua L; Yunsheng L; Li D; Lin D; Chengzhi L; Bingjiang L; Furen Z; Wendi S; Jinnan L; Yu D; Guanshen D; Shi Y
Adv Ther; 2023 Dec; 40(12):5464-5474. PubMed ID: 37824031
[TBL] [Abstract][Full Text] [Related]
15. Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short "Washout" Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy.
Tampouratzi E; Sfaelos K; Talaiporou K; Douvali Τ; Katsantonis J
Acta Dermatovenerol Croat; 2023 Aug; 31(1):48-50. PubMed ID: 37843093
[TBL] [Abstract][Full Text] [Related]
16. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
Hjalte F; Carlsson KS; Schmitt-Egenolf M
Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
[TBL] [Abstract][Full Text] [Related]
17. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
Chaptini C; Quinn S; Marshman G
Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
[TBL] [Abstract][Full Text] [Related]
18. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
Zidane M; Dressler C; Gaskins M; Nast A
JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
Lynde C; Riedl E; Maul JT; Torres T; Pinter A; Fabbrocini G; Daniele F; Brnabic A; Reed C; Wilhelm S; Holzkämper T; Schuster C; Puig L
Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy.
Dastoli S; Passante M; Loconsole F; Mortato E; Balato A; Piccolo V; Guarneri C; Macca L; Provenzano E; Valenti G; D'Amico D; Micali G; Musumeci ML; Palazzo G; Foti C; Romita P; Fabbrocini G; Megna M; Sammarra I; Bennardo L; Patruno C
J Dermatolog Treat; 2023 Dec; 34(1):2200868. PubMed ID: 37026590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]